세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Myeloproliferative Disorders Drugs/Treatment Market is anticipated to experience remarkable expansion, with a projected Compound Annual Growth Rate (CAGR) of 3.48% from 2025 to 2033. According to the market analysis, the market size is forecasted to reach USD 13.82 Billion by the end of 2033, up from USD 10.16 Billion in 2024.

The global myeloproliferative disorders (MPD) drugs and treatment market is set for growth driven by increasing diagnosis rates and advancements in targeted therapies. Novel agents such as JAK inhibitors and interferon formulations are improving disease management and patient outcomes. Future developments will focus on combination therapies, personalized medicine approaches, and novel biomarkers for early detection and treatment monitoring.

Additionally, expanding clinical trials and regulatory approvals are accelerating market availability of innovative treatments. The rise of patient advocacy and awareness programs is enhancing diagnosis and adherence. Advances in genomic profiling and digital health tools are facilitating precision medicine. As hematologic oncology evolves, the MPD drugs and treatment market will continue to innovate, delivering effective, tailored, and safer therapeutic options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Myeloproliferative Disorders Drugs/Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disorder Type

• Philadelphia Chromosome-Positive (Ph+) CML
• Philadelphia Chromosome-Negative (Ph-) MPNs
• Polycythemia Vera
• Essential Thrombocythemia
• Myelofibrosis
• Other Disorder Types

By Drug Class

• Tyrosine Kinase Inhibitors
• Janus Kinase Inhibitors
• Hydroxyurea
• Other Drug Classes

By Route Of Administration

• Oral
• Injectable

By End-Use

• Hospitals
• Specialty Clinics
• Other End-Users
• List of Companies Profiled in the report
• AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc (GSK), GL Pharma GmbH Incyte Corporation, Janssen Biotech Inc. (Johnson & Johnson), MorphoSys AG, Mylan N.V. (Viatris), Novartis Pharmaceuticals Corporation (Novartis AG), Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Disorder Type
  • 3.7.2 Market Attractiveness Analysis By Drug Class
  • 3.7.3 Market Attractiveness Analysis By Route Of Administration
  • 3.7.4 Market Attractiveness Analysis By End-Use
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DISORDER TYPE

• 5.1. Overview By Disorder Type
• 5.2. Historical and Forecast Data Analysis By Disorder Type
• 5.3. Philadelphia Chromosome-Positive (Ph+) CML Historic and Forecast Sales By Regions
• 5.4. Philadelphia Chromosome-Negative (Ph-) MPNs Historic and Forecast Sales By Regions
• 5.5. Polycythemia Vera Historic and Forecast Sales By Regions
• 5.6. Essential Thrombocythemia Historic and Forecast Sales By Regions
• 5.7. Myelofibrosis Historic and Forecast Sales By Regions
• 5.8. Other Disorder Types Historic and Forecast Sales By Regions

6. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 6.1. Overview By Drug Class
• 6.2. Historical and Forecast Data Analysis By Drug Class
• 6.3. Tyrosine Kinase Inhibitors Historic and Forecast Sales By Regions
• 6.4. Janus Kinase Inhibitors Historic and Forecast Sales By Regions
• 6.5. Hydroxyurea Historic and Forecast Sales By Regions
• 6.6. Other Drug Classes Historic and Forecast Sales By Regions

7. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route Of Administration
• 7.2. Historical and Forecast Data Analysis By Route Of Administration
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Injectable Historic and Forecast Sales By Regions

8. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY END-USE

• 8.1. Overview By End-Use
• 8.2. Historical and Forecast Data Analysis By End-Use
• 8.3. Hospitals Historic and Forecast Sales By Regions
• 8.4. Specialty Clinics Historic and Forecast Sales By Regions
• 8.5. Other End-Users Historic and Forecast Sales By Regions

9. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT COMPANIES

• 10.1. Myeloproliferative Disorders Drugs/Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AbbVie Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Bristol-Myers Squibb Company
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Eli Lilly And Company
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. GlaxoSmithKline Plc (GSK)
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. GL Pharma GmbH Incyte Corporation
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Janssen Biotech Inc. (Johnson & Johnson)
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. MorphoSys AG
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Mylan N.V. (Viatris)
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Novartis Pharmaceuticals Corporation (Novartis AG)
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Takeda Pharmaceutical Company Limited
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Teva Pharmaceutical Industries Ltd
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies